KHK6640 clinical trials
Also written KHK6640.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses KHK6640 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KHK6640
- 3
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses KHK6640 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's DiseaseCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02127476Written as KHK6640
- A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's DiseaseCompletedPhase 1Kyowa Kirin Co., Ltd.NCT03093519Written as KHK6640
- A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.CompletedPhase 1Kyowa Kirin Co., Ltd.NCT02377713Written as KHK6640